AN2 Therapeutics Announces Research Collaboration With GSK to Advance Boron-Based LeuRS-Inhibitors Targeting Tuberculosis (TB)Business Wire • 11/10/25
AN2 Therapeutics to Participate in Fireside Chat at Evercore HealthCONx ConferenceBusiness Wire • 11/06/25
AN2 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business and Scientific HighlightsBusiness Wire • 08/12/25
AN2 Therapeutics Commences First-in-Human Clinical Trial of Oral AN2-502998 for Chagas DiseaseBusiness Wire • 08/12/25
AN2 Therapeutics and DNDi Collaborate on Clinical Development of Promising New Oral Compound to Treat Chronic Chagas DiseaseBusiness Wire • 07/23/25
AN2 Therapeutics Reports Key Insights from 200-Patient Observational Study in Acute Melioidosis, Laying Groundwork for Phase 2 Proof-of-Concept Trial of EpetraboroleBusiness Wire • 06/30/25
AN2 Therapeutics Announces Poster Presentation Highlighting M. Abscessus Data at 2025 Colorado Mycobacteria ConferenceBusiness Wire • 05/29/25
AN2 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business and Scientific HighlightsBusiness Wire • 05/13/25
AN2 Therapeutics Reports Data from the Phase 3 Portion of Previously Terminated EBO-301 Study and Outlines Future Milestones from Boron Chemistry PipelineBusiness Wire • 05/01/25
AN2 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business and Scientific HighlightsBusiness Wire • 03/25/25
AN2 Provides Strategic Update for Phase 3 EBO-301 Trial in Treatment Refractory MAC Lung DiseaseBusiness Wire • 02/24/25
AN2 Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceBusiness Wire • 01/29/25
AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry PipelineBusiness Wire • 11/13/24
AN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (caused by Mycobacterium tuberculosis) and MalariaBusiness Wire • 10/17/24
AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceBusiness Wire • 08/28/24
AN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific HighlightsBusiness Wire • 08/13/24
AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung DiseaseBusiness Wire • 08/08/24
Down -5.51% in 4 Weeks, Here's Why AN2 Therapeutics (ANTX) Looks Ripe for a TurnaroundZacks Investment Research • 05/21/24
AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific HighlightsBusiness Wire • 05/14/24